SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ZILA--test for oral cancer?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Fleming who wrote (18)6/11/1996 9:49:00 PM
From: Ivan Andrew   of 61
 
Mark- Thanks for the numbers. ZILA recently (undated) announced (quoting from the press release at zila.com on ZILA's homepage) "it has acquired the remaining two-thirds of the outstanding stock of CTM Associates, the Pennsylvania group that previously held certain rights associated with the first oral cancer diagnostic, OraTestÔ."

In the same release, Joseph Hines said, "OraTest revenue generated through an internal distribution system such as Bio-Dental is expected to be significantly higher than royalty revenue which could be produced by a third-party licensee." He did not give any precise numbers, however, so I found your profit margins highly encouraging. How could we go about verifying those numbers? Are they from an insider? Reliable source?

Thanks,

Ivan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News